ClinicalTrials.gg
CompletedNCT05330858Updated May 9, 2023

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

A Phase 1 interventional study of ESK-001 and Rabeprazole in Pharmacokinetics, sponsored by Alumis Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Alumis Inc · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Men and woman age 18-60
  • Able to provide written
  • Females can not be pregnant or lactating

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to ESK-001
  • History of within the last 10 years
  • Positive for , or C
  • History of tuberculosis
  • Positive test for alcohol or drugs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    ESK-001 Liquid

    ESK-001 administered as an oral liquid

    Drug: ESK-001

  • Experimental
    ESK-001 Tablet Fasted

    ESK-001 administered as an oral tablet in the fasted state

    Drug: ESK-001

  • Experimental
    ESK-001 Tablet Fed

    ESK-001 administered as an oral tablet in the fed state

    Drug: ESK-001

  • Experimental
    ESK-001 and Rabeprazole

    ESK-001 administered as an oral tablet with rabeprazole

    Drug: ESK-001 · Drug: Rabeprazole

Interventions

  • Oral tablet or liquid

  • DrugRabeprazole

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Assess the PK parameters of ESK-001 via time of maximum plasma concentration (Tmax)

    Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms

    Time frame: 18 Days

  2. Assess the PK parameters of ESK-001 via maximum plasma concentration (Cmax)

    Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms

    Time frame: 18 Days

  3. Assess the PK parameters of ESK-001 via area under the concentration time curve (AUC)

    Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms

    Time frame: 18 Days

Secondary outcomes

  1. Assess the Incidence of Treatment Emergent Adverse Events of ESK-001

    Collection and review of incidence of adverse events and serious adverse events

    Time frame: 25 Days

07

Study locations

1 site
  • Alumis Central Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jun 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Apr 15, 2022
StartActual
Mar 17, 2022
Primary completionActual
Jun 30, 2022
CompletionActual
Sep 20, 2022
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05330858
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Mar 17, 2022
Primary completion
Jun 30, 2022
Completion
Sep 20, 2022
Last update
May 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion